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Background: Early diagnosis is the cornerstone of management of acute myocardial infarction (AMI). We aimed to compare the di-
agnostic accuracy of high-sensitivity troponin T (hs-cTnT) with myeloperoxidase (MPO) and pregnancy-associated plasma protein 
A (PAPP-A) for early diagnosis of AMI in patients at the time of presentation to the emergency department (ED). 
Methods: We enrolled 289 patients who presented at the ED of the National Institute of Heart Disease (NIHD) Rawalpindi, Pakistan, 
within 4 hr of onset of chest pain. Clinical assessment, electrocardiography (ECG), and angiography were carried out. Blood sam-
ples were collected at 0, 3, 6, and 12 hr. Analyses of plasma hs-cTnT, MPO, and PAPP-A were carried out using commercial kits.
Results: Out of 289 subjects who presented to the ED, we diagnosed 180 patients with coronary heart disease as having AMI (N= 
61) and 119 as without AMI (stable coronary artery disease, N=61; unstable angina, N=58). Compared to non-AMI patients, the 
patients with AMI had significantly higher levels (represented here as median [inter quartile range]) of plasma hs-cTnT (136 [39-370] 
vs. 12 [7-21] ng/L), MPO (906 [564-1,631] vs. 786 [351-1,299] pmol/L) and PAPP-A (5.78 [2.67-13.4] vs. 2.8 [1.8-4.9] mIU/L). Receiver 
operator characteristic curves (95% CI) for hs-cTnT (0.952 [0.909-0.978]) were significantly higher (P<0.001) than those for MPO 
(0.886 [0.830-0.929]) and PAPP-A (0.797 [0.730-0.854]), with AMI sensitivity and specificity percentages of 87% and 98% (hs-cTnT), 
82% and 84% (MPO), and 65% and 87% (PAPP-A), respectively. 
Conclusions: The diagnostic performance of hs-cTnT was superior to that of MPO and PAPP-A for early triage and diagnosis of AMI 
among patients of coronary heart disease presenting with chest pain to the ED.
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INTRODUCTION
Coronary heart disease (CHD) is primarily the hallmark 
of gradual atherosclerosis, comprising stable coronary ar-
tery disease (SCAD), unstable angina (UA), and acute myo-
cardial infarction (AMI) due to impaired myocardial blood 
supply [1]. Myocardial necrosis is detected on the basis of 
elevated cardiac troponin levels and changes in electrocar-
diography (ECG) patterns in patients presenting with chest 
pain [1]. However, ECG and conventional cardiac biomark-
ers are not sensitive enough for the early diagnosis of AMI 
patients in the emergency department (ED) of hospitals [2]. 
A delay in the diagnosis of AMI increases the risk of com-
plications and reduces the benefit of reperfusion treatment 
[3]. Therefore, early and specific diagnosis of AMI is the 
cornerstone of management of these patients in the coro-
nary care unit and helps avoid unnecessary admissions.
According to current guidelines, patients can be diag-
nosed as having AMI if they have a history of chest pain, 
abnormal ECG changes, and a cardiac troponin value ex-
ceeding the 99th percentile in the reference population [1]. 
However, conventional cardiac troponin assays have low 
sensitivity during the initial few hours after the onset of 
chest pain; as a result, the diagnosis of AMI in the ED is 
challenging. High-sensitivity cardiac troponin T (hs-cTnT) Khan DA, et al.  •  Diagnostic Performance of Novel Cardiac Biomarkers
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assays with lower limits of detection have been recently in-
troduced to overcome this problem in clinical practice. 
Their improved sensitivity may facilitate earlier diagnosis of 
AMI among patients presenting with chest pain [4]. 
Myeloperoxidase (MPO) is an enzyme released from 
neutrophils in response to acute inflammatory changes fol-
lowing myocardial injury. It has been suggested to be an 
early diagnostic marker for acute coronary syndrome [5]. 
Patients with AMI presenting within 2 hr of onset of chest 
pain have been reported to have significantly higher levels 
of MPO than healthy controls. It has therefore been sugges-
ted that measurement of MPO may be useful for the early 
diagnosis of AMI [6].
Pregnancy-associated plasma protein A (PAPP-A) has 
been found to be a useful biomarker for predicting the rup-
ture of unstable atherosclerotic plaques [7, 8]. However, stu-
dies investigating its usefulness in the diagnosis of AMI are 
scant. Iversen and co-workers have recently reported that 
PAPP-A is a more sensitive marker for the diagnosis of AMI 
than troponin T and the creatine kinase isotype CK-MB [9]. 
Multiple cardiac biomarkers, including MPO, PAPP-A, and 
cardiac troponin, have been used for AMI diagnosis in the 
ED setting. However, the sensitivity of cardiac troponin for 
the diagnosis of AMI was observed to be lower within 4 hr 
of chest pain (55%) than at ≥12 hr (97%) after presentation 
at the ED [10]. 
The performance of new high-sensitivity cardiac biomar-
kers of different pathophysiological pathways needs to be 
evaluated for early triage and diagnosis of AMI among pa-
tients presenting with chest pain. We aimed to compare the 
diagnostic accuracy of newly developed hs-cTnT with that 
of MPO and PAPP-A assays, for the early diagnosis of AMI 
among CHD patients who presented at the ED of the Na-
tional Institute of Heart Disease (NIHD) Rawalpindi, Paki-
stan, with recent onset of chest pain.
 
MATERIALS AND METHODS
The comparative study was carried out at the Chemical 
Pathology Department, Army Medical College (AM Col-
lege), Rawalpindi, in collaboration with NIHD, Rawalpindi, 
Pakistan. The research protocol was approved by the ethics 
committee of the AM College, National University of Sci-
ence and Technology (NUST) Islamabad, Pakistan, and 
complies with the Declaration of Helsinki.
1. Patients 
We enrolled 289 consecutive adult male and female pa 
tients aged 35 to 80 yr, who presented to the ED of NIHD 
within 4 hr of onset of chest pain between September 2009 
and March 2010. All patients underwent an initial clinical 
assessment by a cardiologist, which included recording of 
clinical history, physical examination, 12-lead ECG, contin-
uous monitoring, and serial hs-cTnT testing at presentation 
and 0, 3, 6, and 12 hr after onset of chest pain. Coronary ar-
tery angiography was carried out at NIHD. 
Data were reviewed by 2 independent cardiologists for a 
final diagnosis at the time of discharge from the institute. 
We diagnosed 180 CHD patients on the basis of clinical 
findings, ECG, hs-cTnT, and angiography results; these in-
cluded 61 patients with AMI, 58 patients with UA, and 61 
patients with SCAD. AMI was diagnosed, on the basis of 
current guidelines, if the hs-cTnT level was at least one 
value above the 99th percentile with a coefficient of varia-
tion (CV) of 9.2%; if there was a >50% increase or decrease 
in hs-cTnT levels in 2 consecutive samples along with ECG 
changes were indicative of ST segment elevation/depression 
or development of new pathologic Q waves on serial mea-
surements (1). UA was diagnosed in patients with chest 
pain lasting more than 20 min at rest, without elevation in 
hs-cTnT levels and with or without changes in ECG pat-
terns. SCAD was diagnosed if angiography results revealed 
>70% stenosis in one of the main coronary arteries, with a 
history of no significant change in frequency or duration of 
angina on minimal exertion or at rest for at least 60 days, 
and if there was no evidence of recent myocardial damage. 
We excluded 109 patients, including those who presented 
with other cardiac diseases (cardiomyopathies, myocarditis, 
heart failure, AMI with concomitant renal failure), present-
ed with pulmonary or psychiatric problems, died in the ED, 
or were unwilling to participate in the study. 
2. Biochemical analysis
Blood samples were collected in EDTA tubes from all pa-
tients before the administration of heparin. The samples 
were transported immediately to the clinical pathology lab-
oratory of AM College, Rawalpindi, where plasma was sep-
arated by centrifugation at 2,000×g for 15 min. Assays for 
hs-cTnT and MPO were performed immediately after sam-
ple collection, and the remaining samples were stored at 
-80˚C. Analysis of PAPP-A and lipid profile was carried out 
in batches at end of the study.
Biochemical analysis was carried out by qualified labora-
tory technologists according to the validated manufacturer’s 
procedures in the clinical pathology laboratory of AM Col-
lege, Rawalpindi, Pakistan. Total cholesterol, plasma glu-
cose, and serum creatinine were measured on a Selectra E 
Chemistry Analyzer (Vital Scientific NV, DIERN, The Neth-174     www.kjlm.org
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erlands) using kits provided by Pioneer Diagnostics (Pio-
neer, New York, NY, USA).
Assay for hs-cTnT was performed using plasma with an 
electrochemiluminescence-based kit (Elecsys Cobas e 411 
analyzer; Roche Diagnostics, Basel, Switzerland). The lower 
limit of detection for the hs-cTnT assay was 1 ng/L. The as-
say employs 2 monoclonal antibodies specifically directed 
against human cardiac troponin T. The antibodies recog-
nize 2 epitopes (amino acid positions 125-131 and 136-147) 
located in the central part of the cardiac troponin T protein. 
The procedure comprised 2 incubations, the first of which 
involved the sample, a biotinylated monoclonal anti-cardiac 
troponin T antibody, and a monoclonal anti-cardiac tropo-
nin T antibody labelled with a ruthenium complex, which 
together formed a sandwich complex. The reaction mixture 
was aspirated into the measuring cell, where the micropar-
ticles were magnetically captured onto the surface of the 
electrode. Application of a voltage to the electrode then in-
duced chemiluminescent emission, which was measured by 
a photomultiplier, and the values were determined using a 
calibration curve. The CV at 14 ng/L, i.e., 99th percentile 
for the assay was 9.2%.
Plasma MPO was analyzed on the ARCHITECT ci4100 
immunoassay analyzer (Abbott Diagnostic, Chicago, IL, 
USA) by using the chemiluminescent microparticle immu-
noassay kit of the same manufacturer, which has a measur-
ing range of 20-10,000 pmol/L and a CV of 4.7%. The plasma 
MPO levels in the healthy controls were 285 to 540 pmol/L. 
Serum PAPP-A levels were measured by an ultrasensitive 
ELISA kit (IBL International GmbH, Hamburg, Germany) 
using the Evolis automated ELISA processor (Bio-Rad Labo-
ratories, Hercules, CA, USA). This kit has specifically been 
designed for this cardiac biomarker and has a measuring 
range of 0-100 mIU/L. The serum PAPP-A levels in the 
healthy controls were 1.74-5.91 mIU/L, and the CV of the 
assay was 5.1%.
3. Statistical analysis
Statistical analysis was performed using SPSS 16 (SPSS 
Inc., Chicago) and MedCalc software version 9.6.4.0. The 
baseline characteristics are reported as percentage for cate-
gorical variables, mean (SD) for continuous normal distrib-
uted variables, and median and interquartile range (IQR) 
for variables with a skewed distribution. The distribution of 
serum hs-cTnT, PAPP-A, and plasma MPO levels were not 
normal; therefore, the Mann-Whitney test was applied. The 
area under the receiver operator characteristic curves (AUC) 
of the serum levels of hs-cTnT, PAPP-A, and MPO were cal-
culated, and the C-statistic was applied. The ROC curves 
from these 3 assays were compared by the method of De-
Long (11). We set the cutoff value as that at which the dis-
crimination between the cases with positive and negative 
diagnosis is optimal. The diagnostic accuracies of hs-cTnT, 
PAPP-A, and MPO were assessed on the basis of the sensi-
tivity (SN), specificity (SP), likelihood ratio (LR), and diag-
nostic odds ratio (DOR) of the tests. A P value of <0.05 was 
considered significant.
RESULTS
During the study period, 289 patients presented at the 
ED of NIHD within 4 hr of onset of chest pain. One hun-
dred and nine patients were excluded because they had 
non-cardiac and cardiac diseases like cardiomyopathies, 
myocarditis, congestive cardiac failure, and acute coronary 
syndrome (ACS) with renal failure. These patients also in-
cluded 4 who died in the ED and 8 who were not willing to 
participate in the study (Fig. 1). A total of 180 patients (age, 
Excluded
180 patients with CAD
MPO/PAPP-A/hs-cTnT
At 2-4 hours
Final diagnosis (N=180)
Clinical assessment, Angiography
  Positive ECG and serial hs-cTnT (N=241)
hs-cTnT
AMI (N=53)
Non-AMI (N=127)
MPO
AMI (N=50)
Non-AMI (N=130)
AMI
(N=61)
Non-AMI (N=119)
UA (N=58); SCAD (N=61)
PAPP-A
AMI (N=39) 
Non-AMI (N=141)
289 patients presented with
chest pain to ED
Fig. 1. Schematic diagram showing the methodology for classification of 
patients.
Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery dis-
ease; UA, unstable angina; SCAD, stable coronary artery disease; hs-cTnT, 
high-sensitivity cardiac troponin T; MPO, Myeloperoxidase; PAPP-A pregnan-
cy-associated plasma protein A.
∙ 24 Cardiomyopathies, myocarditis, CCF, ACS
  with renal failure)
∙ 38 Musculoskeletal pain
∙ 23 Pain due to gastrointestinal problem
∙ 7 Pain of pulmonary origin
∙ 3 Psychiatric problems
∙ 4 Death in ED
∙ 8 Unwillingness to participateKhan DA, et al.  •  Diagnostic Performance of Novel Cardiac Biomarkers
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35 to 80 yr) with AMI (N=61) and non-AMI (N=119) di-
agnoses therefore constituted the final study population. 
The baseline characteristics of the patients are shown in Ta-
ble 1. Retrosternal chest pain (98%) and sweating (61%) 
were the commonest presenting symptoms of patients with 
AMI, followed by nausea (39%), vomiting (36%), anxiety 
(13%), and shortness of breath (8%). 
1. Diagnostic performance of cardiac biomarkers
Patients with AMI had significantly higher (P<0.001) 
median (IQR) levels of biomarkers than non-AMI patients: 
hs-cTnT, 136 (39-370) ng/L vs. 12 (7-21) ng/L; MPO, 906 
(564-1,631) pmol/L vs. 786 (351-1,299) pmol/L; and PAPP-
A, 5.78 (2.67-13.4) mIU/L vs. 2.8 (1.8-4.9) mIU/L (Fig. 2).
Patients with AMI had significantly higher AUC for hs-
cTnT (95% CI, 0.952 [0.909-0.978]) than for MPO (0.886 
[0.830-0.929]; P=0.028), or PAPP-A (0.797 [0.730-0.854]; 
P<0.001) at the time of presenting to the ED, as shown in 
Fig. 3. The AUC for MPO was also significantly higher than 
that for PAPP-A (P=0.015). 
The sensitivity, specificity, positive LR, negative LR, and 
DOR of hs-cTnT, MPO, and PAPP-A at different cutoff levels 
were calculated (Table 2). The best cutoff value for hs-cTnT 
was 14 ng/L, with a sensitivity and specificity of 87% and 
98%, respectively, for diagnosing AMI. The best cutoff values 
for MPO and PAPP-A were 564 pmol/L and 4.7 mIU/L re-
spectively, with a sensitivity and specificity of 82% and 84% 
for MPO, and 65% and 87% for PAPP-A. On the basis of 
sensitivity, the number of patients with AMI correctly diag-
nosed at admission were 53 (87%), 50 (82%), and 39 (65%), 
by the hs-cTnT, MPO, and PAPP-A assays, respectively. 
Therefore, hs-cTnT had the highest sensitivity for the diag-
nosis of AMI in the ED within 4 hr of onset of chest pain.
DISCUSSION
The early triage of AMI patients who present with clinical 
symptoms suggestive of CHD is a challenging task for doc-
tors. However, the development of the new high-sensitivity 
fifth-generation generation cardiac troponin assay, with its 
very low detection limits, has greatly improved the early di-
agnosis of minor cardiac injury. Admission of patients on 
provisional diagnosis of AMI without proper investigation 
with cardiac biomarkers, often leads to overcrowding and is 
associated with excessive hospital costs.
One potential advantage of a multi-marker approach is 
the rapid diagnosis or exclusion of AMI. cTn measurements 
are essential for the diagnosis of AMI in all patients who 
present with chest pain in the ED. Sampling of conventional 
cTn is necessary at presentation and at intervals of 6, 9, 12, 
and 24 hr. However, our main aim was to diagnose AMI pa-
tients early by using hs-cTnT; therefore, we collected sam-
ples at intervals of 0, 3, 6, and 9 hr. We also compared the 
Table 1. Baseline characteristics of patients diagnosed with and without 
acute myocardial infarction
Characteristic Non-AMI
N=119
AMI
N=61 P value
Age (yr) 57.62 (9.8) 58.34 (8.9) 0.121
Male sex n (%) 99 (83) 51 (84) 0.110
BMI (kg/m
2) 26.89 (4.20) 25.66 (2.57) 0.078
Total cholesterol (mmol/L)  5.30 (0.87) 5.56 (0.94) 0.021
Triglyceride (mmol/L) 1.80 (0.80) 2.13 (0.81) 0.034
Creatinine (µmol/L) 84.83 (2.80) 90.34 (1.74) 0.067
Family history of CHD n (%)  26 (21) 14 (23) 0.071
Diabetes mellitus n (%) 43 (36) 45 (74) 0.005
Hypertension n (%) 73 (61) 37 (60) 0.067
Hyperlipidemia n (%) 51 (42) 36 (59) 0.003
*Data are shown as mean (SD) for continuous variables and number (percentage) for 
categorical variables.
Abbreviations: AMI, Acute myocardial infarction; BMI, Body Mass Index.
Fig. 2. Comparison of high-sensitivity cardiac troponin, myeloperoxidase 
and pregnancy-associated plasma protein A levels between patients with 
AMI (N=61) and without AMI at admission (N=119).
Abbreviations: AMI, acute myocardial infarction; MPO, Myeloperoxidase; 
PAPP-A, pregnancy-associated plasma protein A.
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diagnostic usefulness of newer-generation hs-cTnT with 
MPO and PAPP-A assays for the early detection of AMI in 
patients of CHD presenting with chest pain. The AUC val-
ues showed that the hs-cTnT assay has excellent diagnostic 
ability for patients presenting at the ED within 4 hr of onset 
of chest pain. The number of patients correctly classified at 
4 hr was also the highest when plasma hs-cTnT levels were 
used. This demonstrates that the diagnostic performance of 
hs-cTnT is superior to that of the MPO and PAPP-A assays. 
The AUC values for hs-cTnT noted in our AMI patients at 
the time of admission to ED were similar to those reported 
by Reichlin et al. [4]. The sensitivity and specificity of the hs-
cTnT assay was excellent for early diagnosis of AMI, with a 
cutoff value greater than 14 ng/L at the 99th percentile. Keller 
et al. [12] also reported a higher AUC value with a high-sen-
sitivity troponin I assay than with the conventional troponin 
T assay Standard troponin assays have several limitations. 
When measured 4 hr after the onset of chest pain, their sen-
sitivity and specificity are 35% and 96% respectively [13]. 
Further, they are incapable of determining concentrations in 
a healthy population. Another study demonstrated that use 
of the 99th percentile cutoff for the hs-cTnT assay allows ear-
lier diagnosis of non-ST-elevation myocardial infarction 
(NSTEMI) [14]. Our study supports the previous finding 
that cardiac troponin is more clinically accurate for the early 
diagnosis of AMI [15]. An ideal biochemical marker would 
therefore be one that has high sensitivity and specificity and 
appears early after an AMI. 
The levels of MPO observed in our study were similar to 
those observed by Khan et al. [16] and Mocatta et al. [17]. 
Ndrepepa et al. [18] also found higher circulating levels of 
MPO in patients of AMI than in patients with angina and 
healthy individuals. Elevated levels of PAPP-A in AMI pa-
tients were previously reported by Iversen et al. [9]. Our 
findings differ from those of Brennan et al. with respect to 
the usefulness of MPO in the diagnosis of ACS in patients 
who were consistently negative for Troponin T [6]. They 
used the stan-dard troponin T assay, which has reduced sen-
sitivity at low concentrations. However, the results of our 
study are consistent with the observations of Esporcatte et al. 
Table 2. Diagnostic performance of hs-cTnT, MPO, and PAPP-A at different cutoffs for the diagnosis of AMI at presentation to emergency department
SN % (95% of Cl) SP (%) % (95% of Cl) LR+ % (95% of Cl) LR- % (95% of Cl) DOR % (95% of Cl)
Hs-cTnT (ng/L)
  >12 88 (78-94) 96 (90-98) 22.00 (8.89-49.92) 0.13 (0.06-0.241) 175 (53-579)
  >14 87 (76-93) 98 (94-99) 51.69 (13.06-205.01) 0.13 (0.07-0.22) 387 (79-1887)
  >17 83 (72-90) 98 (94-99) 49.74 (012.53-197.47) 0.17 (0.09-0.29) 298 (63-1410)
MPO (pmol/L)
  >547 83 (72-90) 83 (75-88) 5.03 (3.28-7.53) 0.20 (0.11-0.34) 25 (10-58)
  >564 82 (70-89) 84 (77-90) 5.313 (3.48-8.42) 0.20 (0.12-0.36) 26 (11-58)
  >580 79 (66-87) 84 (76-89) 5.27 (31-75) 0.25 (0.15-0.41) 21 (8-421)
PAPP-A (mIU/L)
  >4.48 66 (53-76) 85 (77-90) 4.14 (2.72-6.88) 0.40 (0.28-0.57) 10 (5-22)
  >4.76 65 (53-76) 87 (79-91) 5.00 (2.98-7.96) 0.40 (0.27-0.56) 13 (5-25)
  >4.9 63 (0.49-0.73) 87 (80-92) 4.85 (2.96-8.24) 0.43 (0.31-0.60) 11 (5-24)
Abbreviations: SN, Sensitivity; SP, Specificity; LR+, Positive likelihood ratio; LR-, Negative likelihood ratio; DOR, Diagnostic odds ratio; MPO, myeloperoxidase; PAPP-A, pregnancy-
associated plasma protein A; hs-cTnT, high-sensitivity cardiac troponin T.
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[19], who reported a diagnostic sensitivity of 92% and speci-
ficity of 40% for identifying AMI patients with acute chest 
pain. Elesber et al. also assessed the levels of PAPP-A in pa-
tients presenting to the ED with acute chest pain suggestive 
of ACS, and reported that PAPP-A levels were predictive of a 
final diagnosis of ACS [20]. Evidence shows that myocardial 
injury not only is related to platelet activation but also in-
volves leukocyte accumulation and activation in the athero-
sclerotic plaque. These leukocytes undergo degranulation in 
the coronary circulation in patients with ACS, which leads 
to the release of MPO and thus accounts for the elevated lev-
els of MPO seen in ACS. More recently, PAPP-A was as-
sessed as a marker of vulnerable plaque in patients with 
ACS, and the number of patients with high-risk ACS (63%) 
reported to have detectable PAPP-A was significantly greater 
than that of patients with low-risk ACS (39%; P<0.001). We 
observed a strong and positive correlation between MPO 
and PAPP-A, which reflects a heightened state of inflamma-
tion in ACS. However, the diagnostic performance of the hs-
cTnT assay used in our study was significantly higher than 
that of both MPO and PAPP-A assays. Research is underway 
to identify a biomarker that can detect ACS before the mani-
festation of full-blown AMI (e.g., MPO and PAPP-A), but 
none have shown potential for use in standard practice for 
diagnosis of AMI because of deficiencies in their diagnostic 
performance. Merits of this study is that we determined the 
cutoff values, sensitivity, specificity, and DOR of biomarkers 
by using newly validated hs-cTnT assays for early diagnosis 
of AMI in patients with CHD in the ED. Our study supports 
the recommendation for the use of hs-cTnT as a single car-
diac biomarker along with ECG for early diagnosis of AMI 
in the emergency setup. We acknowledge the potential limi-
tations of our study, namely, a relatively small sample size 
and lack of evaluation in a typical clinical setting because of 
our strict inclusion criteria of CHD patients only.
 
CONCLUSIONS
We conclude that high-sensitivity troponin enables a more 
rapid and accurate diagnosis of myocardial injury than con-
ventional cardiac biomarkers. The diagnostic performance 
of hs-cTnT is superior to MPO and PAPP-A for early triage 
of AMI among CHD patients presenting with chest pain in 
an emergency medical care setting. 
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